Chiaasyll™ works
without
exerting any pharmacological, immunological or metabolic action or effects on the human body

The studies conducted show that Chiasyll™ has a good safety profile with no serious adverse reactions observed. The safety and tolerability of Chiasyll™ are supported by a number of studies and long market history associated with the efficacy and safety of psyllium and chia seed.

Chiasyll™ achieves its principle intended action without any pharmacological, immunological or metabolic action or effects on the human body. As a result of this non-systemic mechanism of action, products made with Chiasyll™ are certified as a Class IIa medical device* under the Medical Device Directive 93/42/EEC.

 


* What is a Medical Device?

A medical device is amongst others defined as any article, whether used alone or in combination, intended by the manufacturer to be used for human beings for the purpose of: prevention, monitoring, treatment or alleviation of disease and which achieves its principal intended action in or on the human body, not through any pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.

 

 

 

 

Previous | Next

 
Copyright © 2013 by InQpharm Group. All rights reserved. Last updated: July 2013 | ID: MPTL/TM/EN/13/001
Chiasyll and InQpharm are trademarks of the InQpharm group of companies.